China NMPA Drug Inspection - Gansu Lanyao Pharmaceutical Co., Ltd. - Ribavirin Injection

On March 6, 2020, the Gansu Provincial Drug Administration released the results of an emergency quality sampling inspection conducted in February 2020. This regulatory action targeted medications essential for COVID-19 prevention and control to ensure public safety during the epidemic. The inspection involved 38 batches of drugs produced by several prominent manufacturers, including Shijiazhuang Yiling Pharmaceutical Co., Ltd., Sinopharm Rongsheng Pharmaceutical Co., Ltd., Beijing Tongrentang, and Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd. The products tested covered a range of treatments, such as Lianhua Qingwen Capsules, Ribavirin injections, and various Traditional Chinese Medicine (TCM) formulations. Evaluations were performed by the Gansu Provincial Institute for Drug Control based on the regulatory framework of the Chinese Pharmacopoeia (2015 Edition) and relevant National Drug Standards. The inspection results revealed that all 38 batches were 'Qualified,' with no violations or quality issues identified. Because the samples met all safety and efficacy requirements, no corrective actions or penalties were mandated. The document serves as a proactive public disclosure to maintain transparency and confirm the integrity of the drug supply chain during the public health crisis.